Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

(2012) C. F. Deacon et al.   DIABETES OBESITY & METABOLISM

Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment

(2012) M. S. Fineman et al.   DIABETES OBESITY & METABOLISM

Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations

(2012) R. Pencek et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

(2012) John B Buse et al.   LANCET

Exenatide Once Weekly for the Treatment of Type 2 Diabetes Mellitus: Clinical Results in Subgroups of Patients Using Different Concomitant Medications

(2012) Richard Pencek et al.   POSTGRADUATE MEDICINE

Weight-Related Quality of Life, Health Utility, Psychological Well-Being, and Satisfaction With Exenatide Once Weekly Compared With Sitagliptin or Pioglitazone After 26 Weeks of Treatment

(2011) J. H. Best et al.   DIABETES CARE

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study

(2011) D. Russell-Jones et al.   DIABETES CARE

Achieving a clinically relevant composite outcome of an HbA1c of

(2011) B. Zinman et al.   DIABETES OBESITY & METABOLISM

Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes

(2011) Mary Beth DeYoung et al.   Diabetes Technology & Therapeutics

The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review

(2011) Vanita R. Aroda et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

(2011) Thomas Blevins et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

(2011) Goodarz Danaei et al.   LANCET

Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing

(2010) Mark Fineman et al.   CLINICAL PHARMACOKINETICS

Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database

(2010) J. H. Best et al.   DIABETES CARE

Relationship of baseline HbA1cand efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

(2010) R. A. DeFronzo et al.   DIABETIC MEDICINE

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

(2010) Michaela Diamant et al.   LANCET

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

(2010) Richard M Bergenstal et al.   LANCET

Standards of Medical Care in Diabetes--2010

(2009)   DIABETES CARE

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

(2009) J. H. Best et al.   DIABETIC MEDICINE

Translating the A1C Assay Into Estimated Average Glucose Values

(2008) D. M. Nathan et al.   DIABETES CARE

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET